Would you consider adding abiraterone or docetaxel in patients with high risk prostate cancer whose PSA does not become undetectable after ADT and radiotherapy with castrate level testosterone?  


Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution